Trial · NCT01751906
Results by group144
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 144
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Cardiac Death/TV-MI/ID-TLR (TLF) | Absorb BVS | 102 | Participants | ||
| Number of Cardiac Death/TV-MI/ID-TLR (TLF) | XIENCE | 41 | Participants | ||
| Number of Participants With Powered Secondary Endpoint: Angina | Absorb BVS | 238 | Participants | ||
| Number of Participants With Powered Secondary Endpoint: Angina | XIENCE | 125 | Participants | ||
| Number of Participants With Powered Secondary Endpoint: All Revascularization | Absorb BVS | 120 | Participants | ||
| Number of Participants With Powered Secondary Endpoint: All Revascularization | XIENCE | 55 | Participants | ||
| Number of Participants With Powered Secondary Endpoint: Ischemia Driven Target Vessel Revascularization (ID-TVR) | Absorb BVS | 66 | Participants | ||
| Number of Participants With Powered Secondary Endpoint: Ischemia Driven Target Vessel Revascularization (ID-TVR) | XIENCE | 25 | Participants | ||
| Acute Success- Device Success (Lesion Level Analysis) | Absorb BVS | 94.3 | Percentage of lesions | ||
| Acute Success- Device Success (Lesion Level Analysis) | XIENCE | 99.3 | Percentage of lesions | ||
| Acute Success: Procedural Success (Subject Level Analysis) | Absorb BVS | 1240 | Participants | ||
| Acute Success: Procedural Success (Subject Level Analysis) | XIENCE | 652 | Participants | ||
| Number of Death (Cardiac, Vascular, Non-cardiovascular) | Absorb BVS | 85 | Participants | ||
| Number of Death (Cardiac, Vascular, Non-cardiovascular) | XIENCE | 44 | Participants | ||
| Number of Participants With All Myocardial Infarction (MI) | Absorb BVS | 159 | Participants | ||
| Number of Participants With All Myocardial Infarction (MI) | XIENCE | 69 | Participants | ||
| Number of Participants With All Target Lesion Revascularization (TLR) | Absorb BVS | 118 | Participants | ||
| Number of Participants With All Target Lesion Revascularization (TLR) | XIENCE | 51 | Participants | ||
| Number of Participants With All Target Vessel Revascularization (TVR) Excluding Target Lesion Revascularization (TLR) | Absorb BVS | 108 | Participants | ||
| Number of Participants With All Target Vessel Revascularization (TVR) Excluding Target Lesion Revascularization (TLR) | XIENCE | 40 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01751906/results